Loading
NASDAQHealthcareBiotechnology
Latest quote
$2.75
−$0.03 · -1.08%
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Previous close
$2.75
−$0.03 · -1.08%
After-hours
$2.75
$0.00 · 0.00%
Oct 7, 7:30 PM ET
Regular session · ET · Market data may be delayed.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Day range
Current $2.75
52-week range
Current $2.75
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
31
Expensive
Sentiment
54
Mixed
Risk
59
Elevated Risk
Momentum
71
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Day range
Current $2.75
52-week range
Current $2.75
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Research and development | 154.22M USD | 73.28M USD | 27.67M USD | 24.25M USD | 38.4M USD |
| Selling, general, and administrative | 18.27M USD | 17.61M USD | 14.09M USD | 12.28M USD | 12.07M USD |
| Operating expenses | 172.5M USD | 90.89M USD | 41.76M USD | 36.53M USD | 50.47M USD |
| Depreciation and amortization | 350K USD | 318K USD | 311K USD | 318K USD | 326K USD |
| Operating income | −172.5M USD | −90.89M USD | −41.76M USD | −36.53M USD | −50.47M USD |
| Net income | −165.67M USD | −80.6M USD | −36.95M USD | −35.36M USD | −50.64M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$8.00
190.91% upside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 29, 2020 | 1:12 | — | — |
Effective May 29, 2020
1:12
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI8.43M0.00%2.3T USD0.03%$381.03-0.40%
iShares Russell 2000 ETFIWM4.86M0.01%78.56B USD0.19%$277.7-1.29%
Fidelity Enhanced Small Cap ETFFESM2.71M0.04%6.41B USD0.28%$45.22-1.14%
Vanguard Extended Market ETFVXF2.67M0.00%95.4B USD0.05%$233.49-1.56%
iShares Russell 2000 Growth ETFIWO1.76M0.01%14.25B USD0.24%$355.37-1.43%
Vanguard Russell 2000 ETFVTWO1.46M0.01%18B USD0.06%$112.21-1.26%
Dimensional - US Small Cap ETFDFAS1.26M0.00%34.14B USD0.31%$77.92-1.38%
iShares Biotechnology ETFIBB1.01M0.01%10.4B USD0.44%$203.34+0.12%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMFidelity Enhanced Small Cap ETFFESMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
